{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 455169440
| IUPAC_name = ''N''-(''tert''-butyl)-4-{[(1''s'',4''s'')-5'-ethoxy-4-(2-morpholin-4-ylethoxy)-2'-oxospiro[cyclohexane-1,3'-indol]-1'(2<nowiki>'</nowiki>''H'')-yl]sulfonyl}-3-methoxybenzamide
| image = Satavaptan structure.svg
| width = 200
<!--Clinical data-->
| tradename =  
| legal_status =  
| routes_of_administration =  
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 185913-78-4
| ATC_prefix = none
| PubChem = 9810773
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = AJS8S3P31H
<!--Chemical data-->
| C=33 | H=45 | N=3 | O=8 | S=1
| molecular_weight = 643.789 g/mol
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 32699105
| smiles = C1COCCN1CCO[C@H]2CC[C@](CC2)3c4cc(OCC)ccc4N(C3=O)S(=O)(=O)c5ccc(cc5OC)C(=O)NC(C)(C)C
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C33H45N3O8S/c1-6-43-25-8-9-27-26(22-25)33(13-11-24(12-14-33)44-20-17-35-15-18-42-19-16-35)31(38)36(27)45(39,40)29-10-7-23(21-28(29)41-5)30(37)34-32(2,3)4/h7-10,21-22,24H,6,11-20H2,1-5H3,(H,34,37)/t24-,33+
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = QKXJWFOKVQWEDZ-VCCCEUOBSA-N
}}

'''Satavaptan''' ([[International Nonproprietary Name|INN]]; developmental code name '''SR121463''', former tentative brand name '''Aquilda''') is a [[vasopressin receptor antagonist|vasopressin-2 receptor antagonist]]<ref name="pmid17699341">{{cite journal |author=Soupart A |title=Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist |journal=Clin J Am Soc Nephrol |volume=1 |issue=6 |pages=1154–1160 |date=November 2006 |pmid=17699341 |doi=10.2215/CJN.00160106 |url= |name-list-format=vanc|author2=Gross P |author3=Legros JJ |display-authors=3 |last4=Alfoldi |first4=S. |last5=Annane |first5=D. |last6=Heshmati |first6=H. M. |last7=Decaux |first7=G.}}</ref> which was investigation by [[Sanofi-Aventis]] and was under development for the treatment of [[hyponatremia]]. It was also being studied for the treatment of [[ascites]].<ref name="pmid18508290">{{cite journal |author1=Ginès P |author2=Wong F |author3=Watson H |author4=Milutinovic S |author5=Ruiz Del Arbol L |author6=Olteanu D |title=Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: A randomized trial |journal=Hepatology |volume= 48|issue= 1|pages= 204–213|date=February 2008 |pmid=18508290 |doi=10.1002/hep.22293 |url=}}</ref> Development was discontinued in 2009.<ref name="AdisInsight">http://adisinsight.springer.com/drugs/800007591</ref>

==References==
{{Reflist|2}}


{{Oxytocin and vasopressin receptor modulators}}

[[Category:Diuretics]]
[[Category:Hormonal agents]]
[[Category:Vasopressin receptor antagonists]]
[[Category:Tert-butyl compounds]]


{{cardiovascular-drug-stub}}